AMENDMENTS TO THE CLAIMS

1. (Previously Presented) An isolated and purified nucleic acid sequence comprising a polynucleotide

sequence encoding a polypeptide of an antibody, or fragment thereof, wherein said antibody, or

fragment thereof, has binding affinity to a p53 protein or a portion thereof in vertebrates, and

wherein said nucleic acid sequence is obtained from a vertebrate host expressing an immune

response against a naturally-occurring disease.

2. (Previously Presented) The nucleic acid sequence according to claim 1, wherein said immune

response is characterized by expression of at least one p53 antibody.

3. (Previously Presented) The nucleic acid sequence according to claim 1 comprising a

polynucleotide sequence encoding an Fab antibody fragment, or fragment thereof, having binding

affinity to a p53 protein or a portion thereof in vertebrates.

4. (Previously Presented) An isolated and purified nucleic acid sequence encoding a polypeptide of

an antibody, or fragment thereof, comprising a polynucleotide sequence selected from the group

consisting of SEQ ID Nos 1-30, wherein said antibody, or fragment thereof, has binding affinity to a

p53 protein or a portion thereof.

5. (Previously Presented) The nucleic acid sequence according to claim -1, wherein the nucleic acid

sequence is DNA.

6. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the nucleic acid

sequence is RNA.

7. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the nucleic acid

sequence comprises a polynucleotide sequence or sequences, or an analogue thereof, encoding an

antibody fragment or other immunologically active fragment thereof, -wherein the antibody, or

fragment thereof, has binding affinity to a p53 protein or a portion thereof in vertebrates.

2

Serial No. 09/936,964 Attorney Docket No. 01-1242

300 South Wacker Drive, 31st Floor Chicago, IL 60606

McDonnell Boehnen Hulbert & Berghoff LLP

8. (Previously Presented) The nucleic acid sequence according to claim 7, wherein the antibody

fragment or other immunologically active fragment comprises at least one complementarity

determining region.

9. (Previously Presented) The nucleic acid sequence according to claim 7, wherein the antibody

fragment comprises at least one functional antigen-binding domain.

10. (Previously Presented) The nucleic acid sequence according to claim 7, wherein the antibody

fragment is selected from the group consisting of: Fv, Fab, F(ab)2, scFv (single chain Fv), dAb (single

domain antibody), bi-specific antibodies, diabodies and triabodies.

11. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues of one or more of the N-terminus, the C-terminus

or the central domain of a p53 protein or a portion thereof.

12. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues of the N-terminus of a p53 protein or a portion

thereof.

13. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues about 10 to about 55 of the N-terminus of a p53

protein or portion thereof.

14. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues about 10 to about 25 of the N-terminus of a p53

protein or portion thereof.

McDonnell Boehnen Hulbert & Berghoff LLP

15. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues about 40 to about 50 of the N-terminus of a p53

protein or portion thereof.

16. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues about 27 to about 44 of the N-terminus of a p53

protein or portion thereof.

17. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues about 40 to about 44 of the N-terminus of a p53

protein or portion thereof.

18. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the antibody, or

fragment thereof, has binding affinity for residues of the central domain of a p53 protein or a portion

thereof.

19. (Previously Presented) The nucleic acid sequence according to claim 1, wherein said sequence

comprises a polynucleotide sequence encoding a polypeptide of an antibody, or fragment thereof,

having binding affinity to a p53 protein or a portion thereof in vertebrates, wherein said

polynucleotide sequence encodes an immunoglobulin light chain variable region polypeptide or an

immunoglobulin heavy chain variable region polypeptide.

20. (Previously Presented) The nucleic acid sequence according to claim 1, wherein said sequence

comprises a polynucleotide sequence encoding a polypeptide of an antibody, or fragment thereof,

having binding affinity to a p53 protein or a portion thereof in vertebrates, wherein said nucleic acid

sequence comprises a first polynucleotide sequence encoding an immunoglobulin light chain variable

region polypeptide, and a second polynucleotide sequence encoding an immunoglobulin heavy chain

variable region polypeptide.

4

Serial No. 09/936,964 Attorney Docket No. 01-1242

300 South Wacker Drive, 31st Floor Chicago, IL 60606

(312)913-0001

McDonnell Boehnen Hulbert & Berghoff LLP

21. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the vertebrate is

selected from the group consisting of human, non-human primate, murine, bovine, ovine, equine,

caprine, leporine, avian, feline and canine.

22. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the vertebrate is

human.

23. (Previously Presented) An isolated and purified nucleic acid sequence comprising an analogue of

the nucleic acid sequence according to claim 1, wherein said analogue encodes a polypeptide having

a biological activity which is functionally the same as the polypeptide (s) encoded by said

polynucleotide sequence.

24. (Previously Presented) The nucleic acid sequence according to claim 1, wherein the disease is

selected from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

25. (Previously Presented) The nucleic acid sequence according to claim 24, wherein the disease is

cancer.

26. (Previously Presented) The nucleic acid sequence according to claim 25, wherein the cancer is

selected from the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-

rectal cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer,

ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital

tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic

tumors, such as B cell lymphoma.

27. (Previously Presented) A polypeptide of an antibody, or fragment thereof, having binding affinity

to a p53 protein or a portion thereof in vertebrates, wherein said polypeptide is obtained from a

vertebrate host expressing an immune response against a naturally-occurring disease.

5

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

28. (Previously Presented) The polypeptide according to claim 27, wherein said immune response is

characterized by expression of at least one p53 antibody.

29. (Previously Presented) An isolated and purified polypeptide, wherein said polypeptide is encoded

by the nucleic acid sequence according to claims 1.

30. (Previously Presented) An isolated and purified polypeptide of an antibody, or fragment thereof,

comprising an amino acid sequence selected from the group consisting of SEQ ID Nos 31-60,

wherein said antibody, or fragment thereof, has binding affinity to a p53 protein or a portion thereof.

31. (Previously Presented) A polypeptide according to claim 27, wherein said polypeptide is selected

from the group consisting of: Fv, Fab, F(ab)2, scFv (single chain Fv), dAb (single domain antibody), bi-

specific antibodies, diabodies and triabodies.

32. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity to a p53 protein or a portion thereof.

33. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues of one or more of the N-terminus, the C-terminus or the central domain of

a p53 protein or a portion thereof.

34. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues of the N-terminus of a p53 protein or a portion thereof.

35. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues about 10 to about 55 of the N-terminus of a p53 protein or portion

thereof.

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

6

Serial No. 09/936,964 Attorney Docket No. 01-1242

Chicago, IL 60606 (312)913-0001 36. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues about 10 to about 25 of the N-terminus of a p53 protein or portion

thereof.

37. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues about 40 to about 50 of the N-terminus of a p53 protein or portion

thereof.

38. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues about 27 to about 44 of the N-terminus of a p53 protein or portion

thereof.

39. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues about 40 to about 44 of the N-terminus of a p53 protein or portion

thereof.

40. (Previously Presented) The polypeptide according to claim 27, wherein said polypeptide has

binding affinity for residues of the central domain of a p53 protein or a portion thereof.

41. (Previously Presented) An isolated and purified polypeptide, wherein said polypeptide is a

homologous polypeptide of the polypeptide according to claim 27.

42. (Previously Presented) The polypeptide according to claim 41, wherein said polypeptide is at

least 45% homologous to a polypeptide of an antibody or fragment thereof, having binding affinity to

a p53 protein or a portion thereof in vertebrates, wherein said polypeptide of an antibody is obtained

from a vertebrate host expressing an immune response against a naturally-occurring disease.

43. (Previously Presented) The polypeptide according to claim 41, wherein said polypeptide is at

least 75% homologous to the polypeptide of an antibody, or fragment thereof, having binding affinity

to a p53 protein or a portion thereof in vertebrates, wherein said polypeptide of an antibody is

7

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

obtained from a vertebrate host expressing an immune response against a naturally-occurring

disease.

44. (Previously Presented) The polypeptide according to claim 41, wherein said polypeptide is at

least 95-99% homologous to the polypeptide of an antibody, or fragment thereof, having binding

affinity to a p53 protein or a portion thereof in vertebrates, wherein said polypeptide of an antibody is

obtained from a vertebrate host expressing an immune response against a naturally-occurring

disease.

45. (Previously Presented) The polypeptide according to claim 27, wherein the disease is selected

from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

46. (Previously Presented) The polypeptide according to claim 45, wherein the disease is cancer.

47. (Previously Presented) The polypeptide according to claim46, wherein the cancer is selected

from the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-rectal

cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer,

ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital

tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic

tumors, such as B cell lymphoma.

48. (Original) A peptide fragment of the polypeptide of any one of SEQ ID Nos 31-60, wherein said

peptide fragment induces an immune response when administered to a vertebrate.

49. (Previously Presented) The peptide fragment according to claim 48, wherein said peptide

fragment comprises between about 5 and about 50 contiguous amino acids of any one of SEQ ID

Nos 31-60.

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

8

Serial No. 09/936,964 Attorney Docket No. 01-1242

Chicago, IL 60606 (312)913-0001 50. (Previously Presented) The peptide fragment according to claim 48, wherein said peptide

fragment comprises between about 5 and about 30 contiguous amino acids of any one of SEQ ID

Nos 31-60.

51. (Previously Presented) The peptide fragment according to claim 48, wherein said peptide

fragment comprises between about 8 and about 20 contiguous amino acids of any one of SEQ ID

Nos 31-60.

52. (Previously Presented) The peptide fragment according to claim 48, wherein said peptide

fragment is derived from the complementarity determining region.

53. (Previously Presented) The peptide fragment according to claim 48, wherein said immune

response is an idiotypic response.

54. (Previously Presented) The peptide fragment according to claim 48, wherein the vertebrate is

human.

55. (Original) An antibody or fragment thereof, wherein said antibody or fragment thereof has binding

affinity to a p53 protein or a portion thereof in vertebrates, and wherein said antibody is obtained

from a vertebrate host expressing an immune response against a naturally-occurring disease.

56. (Previously Presented) The antibody or fragment thereof according to claim 55, wherein said

immune response is characterized by expression of a p53 antibody.

57. (Previously Presented) The antibody, or fragment thereof, having binding affinity to a p53 protein

or a portion thereof in vertebrates, wherein said antibody or fragment thereof is comprised of the

polypeptide according to claim 27.

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

9

Serial No. 09/936,964 Attorney Docket No. 01-1242

Chicago, IL 60606 (312)913-0001 58. (Previously Presented) The antibody, or fragment thereof, having binding affinity to a p53 protein

or a portion thereof in vertebrates, wherein said antibody or fragment thereof is encoded by the

nucleic acid sequence according to claim 1.

59. (Previously Presented) The antibody fragment according to claim 55, wherein said fragment is an

immunologically active fragment.

60. (Previously Presented) The antibody fragment according to claim 55, wherein said fragment

comprises at least one complementarity determining region.

61. (Previously Presented) The antibody fragment according to claim 55, wherein said fragment is

selected from the group consisting of: Fv, Fab, F(ab)2, scFv (single chain Fv), dAb (single domain

antibody), bi-specific antibodies, diabodies and triabodies.

62. (Previously Presented) The antibody, or fragment thereof, according to claim 55, which is a

polyclonal antibody.

63. (Previously Presented) The antibody, or fragment thereof, according to claim 55, which is a

monoclonal antibody.

64. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues of one or more of the N-terminus, the C-

terminus or the central domain of a p53 protein or a portion thereof.

65. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues of the N-terminus of a p53 protein or a

portion thereof.

McDonnell Boehnen Hulbert & Berghoff LLP

66. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues about 10 to about 55 of the N-terminus

of a p53 protein or portion thereof.

67. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues about 10 to about 25 of the N-terminus

of a p53 protein or portion thereof.

68. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues about 40 to about 50 of the N-terminus

of a p53 protein or portion thereof.

69. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues about 27 to about 44 of the N-terminus

of a p53 protein or portion thereof.

70. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues about 40 to about 44 of the N-terminus

of a p53 protein or portion thereof.

71. (Previously Presented) The antibody or fragment thereof according to claim 57, wherein said

antibody or fragment thereof has binding affinity for residues of the central domain of a p53 protein

or a portion thereof.

72. (Previously Presented) The antibody or fragment thereof according to claim 55, wherein the

disease is selected from the group consisting of cancer, rheumatoid arthritis and coronary heart

disease.

300 South Wacker Drive, 31st Floor

73. (Previously Presented) The antibody or fragment thereof according to claim 72, wherein the

disease is cancer.

McDonnell Boehnen Hulbert & Berghoff LLP

74. (Previously Presented) The antibody or fragment thereof according to claim 73, wherein the

cancer is selected from the group consisting of carcinogenic tumors; tumors of epithelial origin, such

as colo-rectal cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic

cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and

urinary/genital tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and

haemopoietic tumors, such as B cell lymphoma.

75. (Previously Presented) A vector comprising the nucleic acid sequence according to claim 1.

76. (Previously Presented) The vector according to claim 75, wherein said vector is selected from

the group consisting of viral, plasmid, bacteriophage, phagemid, cosmid, bacterial artificial

chromosome, and yeast artificial chromosome.

77. (Previously Presented) The vector according to claim 76, wherein said bacteriophage is selected

from the group consisting of $\lambda gt10$ and $\lambda gt11$ and phage display vectors.

78. (Previously Presented) The vector according to claim 77, wherein said phage display vector is

selected from vectors derived from pCOMB vectors.

79. (Previously Presented) The vector according to claim 76, wherein said phage display vector is of

the MCO group.

80. (Previously Presented) The vector according to any one of claims 77, wherein said phage display

vector is selected from the group consisting of MCO1, MCO3 and MCO6 vectors.

81. (Previously Presented) The vector according to claim 77, wherein said phage display vector is

MC03.

300 South Wacker Drive, 31st Floor

McDonnell Boehnen Hulbert & Berghoff LLP

82. (Previously Presented) The vector according to claim 75, wherein said vector is a mammalian

expression vector.

83. (Previously Presented) The vector according to claim 82, wherein said mammalian expression

vector is pG1D102-MCO or pKN100-MCO.

84. (Previously Presented) A host cell transformed with the vector according to claim 75.

85. (Previously Presented) The host cell according to claim 84, wherein said host cell is selected

from the group consisting of E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, and

Serratia.

86. (Previously Presented) The host cell according to claim 84, wherein said host cell is selected

from the group consisting of yeast, fungi, plant, insect cells and mammalian cells.

87. (Previously Presented) The host cell according to claim 86, wherein said mammalian cells are

selected from the group consisting of CHO cell lines, COS cell lines, HeLa cells, L cells, murine 3T3

cells, c6 glioma cells and myeloma cell lines.

88. (Previously Presented) The host cell according to claim 86, wherein said mammalian cells are

CHO DG44 cells.

89. (Previously Presented) A non-human vertebrate comprising a host cell according to claim 84.

90. (Previously Presented) A pharmaceutical composition comprising the polypeptide according to

claim 27 together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

91. (Previously Presented) The pharmaceutical composition according to claim 90, wherein said

polypeptide is in a form selected from the group consisting of polypeptide/chelate,

13

McDonnell Boehnen Hulbert & Berghoff LLP

polypeptide/drug, polypeptide/prodrug, polypeptide/toxin, polypeptide/imaging marker, antibody/chelate, antibody/drug, antibody/prodrug, antibody/toxin and antibody/imaging marker.

92. (Previously Presented) The pharmaceutical composition according to claim 91, wherein said chelate is selected from the group consisting of: ⁹⁰Y, ¹³¹I and ¹⁸⁸Re.

93. (Previously Presented) The pharmaceutical composition according to claim 91, wherein said drug is a cytotoxic drug.

94. (Previously Presented) The pharmaceutical composition according to claim 93, wherein said cytotoxic drug is selected from the group consisting of adriamycin, melphalan, cisplatin, taxol, fluorouricil, cyclophosphamide.

95. (Previously Presented) The pharmaceutical composition according to claim 91, wherein said prodrug is an antibody directed prodrug therapy or ADEPT.

96. (Previously Presented) The pharmaceutical composition according to claim 91, wherein said toxin is selected from the group consisting of ricin, abrin, *Diptheria* toxin and *Pseudomonas* endotoxin (PE 40).

97. (Previously Presented) The pharmaceutical composition according to claim 91, wherein said imaging marker is selected from the group consisting of ¹²⁵1, ¹³¹I, ¹²³I, ¹¹¹In, ¹⁰⁵Rh, ¹⁵³Sm ⁶⁷Cu ¹⁶⁶Ho, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, and ^{99m}Tc.

98. (Previously Presented) The pharmaceutical composition according to claim 91, wherein said imaging marker is gadolinium.

99. (Previously Presented) A vaccine comprising a nucleic acid sequence according to claim 1, or a fragment thereof, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

April 19, 2005

100. (Previously Presented) The vaccine according to claim 99, wherein said vaccine is an idiotypic

vaccine.

101. (Previously Presented) The vaccine according to claim 99, wherein said vaccine is formulated

for administration via an oral, inhalation, topical or parenteral route.

102. (Previously Presented) A method for inducing an immune response against disease in a

vertebrate, comprising administering to said vertebrate an immunologically effective amount of the

polypeptide, or peptide fragment thereof, according to claim 27.

103. (Previously Presented) The method according to claim 102, wherein the polypeptide, peptide

fragment, or antibody, or fragment thereof, is administered together with a pharmaceutically

acceptable carrier, adjuvant and/or diluent.

104. (Previously Presented) A method for the treatment and/or prophylaxis of disease in a vertebrate

in need of said treatment and/or prophylaxis, wherein said method comprises administering to said

vertebrate a therapeutically effective amount of the polypeptide, or peptide fragment thereof,

according to claim 27.

105. (Previously Presented) The method according to claim 102, wherein the disease is selected

from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

106. (Previously Presented) The method according to claim 102, wherein the disease is cancer.

107. (Previously Presented) The method according to claim106, wherein the cancer is selected from

the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-rectal cancer,

breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer, ovarian

cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract

cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic tumors,

such as B cell lymphoma.

McDonnell Boehnen Hulbert & Berghoff LLP

15

Serial No. 09/936,964 Attorney Docket No. 01-1242

300 South Wacker Drive, 31st Floor Chicago, IL 60606 (312)913-0001 108. (Previously Presented) A diagnostic kit for the detection of polypeptides encoded by the p53 gene in vertebrates, said kit comprising the antibody, or fragment thereof, according to claim 55, together with a diagnostically acceptable carrier and/or diluent.

109. (Previously Presented) The diagnostic kit according to claim 108, wherein said kit comprises:

- (a) a first container containing the antibody, or fragment thereof, wherein said antibody or fragment thereof has binding affinity to a p53 protein or a portion thereof in vertebrates, and wherein said antibody is obtained from a vertebrate host expressing an immune response against a naturally-occurring disease, and;
- (b) a second container containing a conjugate comprising a binding partner of the antibody, or fragment thereof, together with a detectable label.

110. (Previously Presented) A method for screening for a disease in a vertebrate comprising:

- (a) contacting a sample from a vertebrate with a nucleic acid probe comprising a nucleic acid sequence according to claim 1, or an oligonucleotide fragment thereof, and
- (b) detecting hybridization between the nucleic acid sample and the polynucleotide sequence.
- 111. (Previously Presented) The method according to claim 110, wherein the oligonucleotide fragment is between about 10 to about 100 nucleotides in length.
- 112. (Previously Presented) The method according to claim 110, wherein the oligonucleotide fragment is between about 15 to about 30 nucleotides in length.

- 113. (Previously Presented) The method according to claim 110, wherein hybridization as compared to non-hybridization is indicative of disease.
- 114. (Previously Presented) The method according to any one of claims 110, wherein said disease is cancer.
- 115. (Previously Presented) The method according to claim 110, wherein hybridization is conducted under low, moderate, or high stringency.
- 116. (Previously Presented) The method according to claim 110, wherein hybridization is conducted under high stringency.
- 117. (Previously Presented) A method for screening for a disease in a vertebrate comprising:
 - (a) contacting a sample from a vertebrate with the antibody, or fragment thereof, according to claim 55, and
 - (b) detecting the presence of the antibody, or fragment thereof, bound to a p53 polypeptide.
- 118. (Previously Presented) The method according to claim 117, wherein said disease is cancer.
- 119. (Previously Presented) A method of gene therapy, wherein said method comprises:
 - (a) inserting a nucleic acid sequence according to claim 1 into a host cell;
 - (b) expressing the nucleic acid sequence in the transformed cell.
- 120. (Original) The method according to claim 119, wherein said vector is an expression vector.

- 121. (Previously Presented) A process for preparing an antibody, or fragment thereof, having binding affinity to a p53 protein or a portion thereof in vertebrates, wherein said process comprises:
 - (a) isolating from a vertebrate a nucleic acid sequence according to claim 1;
 - (b) cloning said nucleic acid sequence into a vector;
 - (c) constructing an antibody fragment library; and
 - (d) screening said library for clones expressing the antibody of interest.
- 122. (Previously Presented) The process according to claim 121, wherein said antibody, or fragment thereof, has binding affinity to a p53 protein or a portion thereof in vertebrates.
- 123. (Original) The process according to claim 121, wherein said nucleic acid sequence is obtained from an organ suffering from or a collection point for expression of, the disease.
- 124. (Original) The process according to claim 123, wherein said organ is a lymph node.
- 125. (Previously Presented) The process according to claim 121, wherein the vector is a phage display vector.
- 126. (Original) The process according to claim 125, wherein the vector is selected from the group consisting of MCO1, MCO3 and MCO6.
- 127. (Previously Presented) The process according to claim 125, wherein the vector is MC01.
- 128. (Previously Presented) A method of locating a nucleotide sequence encoding a polypeptide of an antibody, or fragment thereof, having binding affinity to a p53 protein or portion thereof in

vertebrates, using the nucleic acid sequence according to claim 1, or an oligonucleotide fragment thereof.

129. (Previously Presented) The method according to claim 128, comprising:

(a) contacting a biological sample with a nucleic acid sequence comprising a polynucleotide sequence encoding a polypeptide of an antibody, or fragment thereof, wherein said antibody, or fragment thereof, has binding affinity to a p53 protein or a portion thereof in vertebrates, and wherein said nucleic acid sequence is obtained from a vertebrate host expressing an immune response against a naturally-occurring disease or an oligonucleotide fragment thereof; and

(b) identifying nucleotide sequences in the biological sample which hybridize to said nucleic acid sequence or oligonucleotide fragment.

130. (Previously Presented) The method according to claim 129, wherein the oligonucleotide fragment is between about 10 to about 100 nucleotides in length.

131. (Previously Presented) The method according to claim 129, wherein the oligonucleotide fragment is between about 15 to about 30 nucleotides in length.

132. (Previously Presented) A pharmaceutical composition comprising a peptide fragment according to claim 48 together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

133. (Previously Presented) A pharmaceutical composition comprising an antibody or fragment thereof according to claim 55 together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

134. (Previously Presented) A vaccine comprising a polypeptide according to claim 27 together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

135. (Previously Presented) The vaccine according to claim 134, wherein said vaccine is an

idiotypic vaccine.

136. (Previously Presented) The vaccine according to claim 134, wherein said vaccine is formulated

for administration via an oral, inhalation, topical or parenteral route.

137. (Previously Presented) A vaccine comprising a peptide fragment according to claim 48

together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

138. (Previously Presented) The vaccine according to claim 137, wherein said vaccine is an

idiotypic vaccine.

139. (Previously Presented) The vaccine according to claim 137, wherein said vaccine is formulated

for administration via an oral, inhalation, topical or parenteral route.

140. (Previously Presented) A vaccine comprising an antibody or fragment thereof according to

claim 55, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

141. (Previously Presented) The vaccine according to claim 140, wherein said vaccine is an

idiotypic vaccine.

142. (Previously Presented) The vaccine according to claim 140, wherein said vaccine is formulated

for administration via an oral, inhalation, topical or parenteral route.

143. (Previously Presented) A method for inducing an immune response against disease in a

vertebrate, comprising administering to said vertebrate an immunologically effective amount of the

peptide fragment according to claim 48.

20

McDonnell Boehnen Hulbert & Berghoff LLP

144. (Previously Presented) The method according to claim 143, wherein the polypeptide, peptide

fragment, or antibody, or fragment thereof, is administered together with a pharmaceutically

acceptable carrier, adjuvant and/or diluent.

145. (Previously Presented) A method for the treatment and/or prophylaxis of disease in a

vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises

administering to said vertebrate a therapeutically effective amount of the peptide fragment according

to claim 48.

146. (Previously Presented) The method according to claim 143, wherein the disease is selected

from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

147. (Previously Presented) The method according to claim 143, wherein the disease is cancer.

148. (Previously Presented) The method according to claim 147, wherein the cancer is selected

from the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-rectal

cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer,

ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital

tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic

tumors, such as B cell lymphoma.

149. (Previously Presented) A method for inducing an immune response against disease in a

vertebrate, comprising administering to said vertebrate an immunologically effective amount of the

antibody, or fragment thereof, according to claim 55.

150. (Previously Presented) The method according to claim 149, wherein the polypeptide, peptide

fragment, or antibody, or fragment thereof, is administered together with a pharmaceutically

acceptable carrier, adjuvant and/or diluent.

21

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

151. (Previously Presented) A method for the treatment and/or prophylaxis of disease in a

vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises

administering to said vertebrate a therapeutically effective amount of the antibody, or fragment

thereof, according to claim 55.

152. (Previously Presented) The method according to claim 149, wherein the disease is selected

from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

153. (Previously Presented) The method according to claim 149, wherein the disease is cancer.

154. (Previously Presented) The method according to claim 153, wherein the cancer is selected

from the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-rectal

cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer,

ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital

tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic

tumors, such as B cell lympohoma.

155. (Previously Presented) A method for inducing an immune response against disease in a

vertebrate, comprising administering to said vertebrate an immunologically effective amount of the

pharmaceutical composition according to claim 90.

156. (Previously Presented) The method according to claim 155, wherein the polypeptide, peptide

fragment, or antibody, or fragment thereof, is administered together with a pharmaceutically

acceptable carrier, adjuvant and/or diluent.

157. (Previously Presented) A method for the treatment and/or prophylaxis of disease in a

vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises

administering to said vertebrate a therapeutically effective amount of the pharmaceutical

composition according to claim 90.

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

158. (Previously Presented) The method according to claim 155, wherein the disease is selected

from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

159. (Previously Presented) The method according to claim 155, wherein the disease is cancer.

160. (Previously Presented) The method according to claim 159, wherein the cancer is selected

from the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-rectal

cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer,

ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital

tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic

tumors, such as B cell lymphoma.

161. (Previously Presented) A method for inducing an immune response against disease in a

vertebrate, comprising administering to said vertebrate an immunologically effective amount of the

vaccine according to claim 99.

162. (Previously Presented) The method according to claim 161, wherein the polypeptide, peptide

fragment, or antibody, or fragment thereof, is administered together with a pharmaceutically

acceptable carrier, adjuvant and/or diluent.

163. (Previously Presented) A method for the treatment and/or prophylaxis of disease in a

vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises

administering to said vertebrate a therapeutically effective amount of the pharmaceutical

composition according to claim 99.

164. (Previously Presented) The method according to claim 161, wherein the disease is selected

from the group consisting of cancer, rheumatoid arthritis and coronary heart disease.

165. (Previously Presented) The method according to claim 161, wherein the disease is cancer.

23

McDonnell Boehnen Hulbert & Berghoff LLP

300 South Wacker Drive, 31st Floor

166. (Previously Presented) The method according to claim 165, wherein the cancer is selected from the group consisting of carcinogenic tumors; tumors of epithelial origin, such as colo-rectal cancer, breast cancer, lung cancer, head and neck tumors, hepatic cancer, pancreatic cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract cancer, oesophageal cancer; mesenchymal tumors, such as sarcoma; and haemopoietic tumors, such as B cell lymphoma.

167. (Previously Presented) A method of gene therapy, wherein said method comprises:

- (a) inserting a vector according to claim 75 into a host cell;
- (b) expressing the nucleic acid sequence in the transformed cell.